Release Details

Five oral presentations and 10 poster presentations focus on Voyager’s clinical and preclinical programs, novel capsid optimization efforts and manufacturing capabilities

Investor and analyst breakfast event at ASGCT scheduled for Friday, May 18, 2018

CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) taking place May 16-19, 2018, in Chicago, Ill.  Data at this year’s meeting includes five oral presentations and 10 poster presentations related to Voyager’s lead clinical program for Parkinson’s disease, its preclinical programs targeting a monogenic form of Amyotrophic Lateral Sclerosis (ALS) called SOD1, Huntington’s disease, and Friedreich’s ataxia, and its gene therapy vector platform including novel adeno-associated virus (AAV) capsid optimization efforts and manufacturing capabilities.  

Details on all abstracts accepted for presentation can be found through ASGCT’s online planner https://plan.core-apps.com/asgct2018

Titles, dates, local times and locations for Voyager Therapeutics’ oral presentations:

Title: “Alzheimer’s Disease: From Genetics to Pathogenesis to Gene Therapy”
Session: 106 Gene Therapy for Alzheimer’s and Related Disorders
Date/time: Wednesday, May 16, 2018, 8:00 a.m.
Location: Waldorf

Title: “Pharmacology and Safety of VY-HTT01, an AAV miRNA Gene Therapy Targeting Huntingtin for the Treatment of Huntington’s Disease”
Session: 114 RNA Virus Vectors and Small RNA Therapy
Date/time: Wednesday, May 16, 2018, 11:15 a.m.
Location: Salon A-3,4

Title: “AADC Gene Therapy for Advanced Parkinson's Disease: Interim Results of a Phase 1b Trial”
Session: 143 Translational and Clinical Progress in Neurological Disease
Date/time: Wednesday, May 16, 2018, 5:00 p.m.
Location: Salon A-1/2

Title: “Safety and Increased Transduction Efficiency in the Adult Nonhuman Primate Central Nervous System with Intravenous Delivery of Two Novel Adeno-Associated Virus Capsids”
Session: 342 Capsid Engineering
Date/time: Friday, May 18, 2018, 4:30 p.m.
Location: Continental Ballroom ABC

Title: “Rescue of Central and Peripheral Neurological Phenotype in a Mouse Model of Friedreich’s Ataxia by Intravenous Delivery of AAV Frataxin with a Novel Capsid”
Session: 343 Preclinical Approaches in Gene Transfer to the Central Nervous System
Date/time: Friday, May 18, 2018, 5:30 p.m.
Location: Salon A-1/2

Titles, dates, local times and locations for Voyager Therapeutics’ poster presentations:

Title: “Biophysical and In Vitro Comparability Analysis of an AAV Vector Produced by the Baculovirus/Sf9 System and HEK Triple Transfection System”
Date/time: Wednesday, May 16, 2018, 5:30 p.m.
Location: P100, Stevens Salon C, D

Title: “Intraoperative MRI-Guided Delivery of AAV2-hAADC for Parkinson’s Disease: Role of Volume of Infusion in Putaminal Gene Expression”
Date/time: Wednesday, May 16, 2018, 5:30 p.m.
Location: P271, Stevens Salon C, D

Title: “Distribution and Transduction of Multiple rAAV Serotype/Mutant Vectors in the Non-Human Primate Brain after Intracisternal Injection by an AAV DNA/RNA Barcoding Library”
Date/time: Thursday, May 17, 2018, 5:15 p.m.
Location: P384, Stevens Salon C, D

Title: “In Vivo Selection of CNS-Specific Novel AAV Capsid Variants by Directed Evolution”
Date/time: Thursday, May 17, 2018, 5:15 p.m.
Location: P393, Stevens Salon C, D

Title: “Selection of an AAV Gene Therapy Targeting SOD1 for the Treatment of SOD1-ALS”
Date/time: Thursday, May 17, 2018, 5:15 p.m.
Location: P555, Stevens Salon C, D

Title: “Evaluation of a New pan-AAV Affinity Resin for rAAV Purification and cGMP Manufacturing”
Date/time: Thursday, May 17, 2018, 5:15 p.m.
Location: P631, Stevens Salon C, D

Title: “Insect Media Evaluation for Cell Growth and rAAV Production in an Sf9-Baculovirus Manufacturing System”
Date/time: Thursday, May 17, 2018, 5:15 p.m.
Location: P640, Stevens Salon C, D

Title: “Evaluation of a Biological Potency Assay for an AAV2.AADC Vector Used in the Treatment of Parkinson’s Disease”
Date/time: Friday, May 18, 2018, 5:45 p.m.
Location: P916, Stevens Salon C, D

Title: “Development and Evaluation of High Throughput Scale-down Models for rAAV Chromatographic Separations for Application in cGMP Manufacturing”
Date/time: Friday, May 18, 2018, 5:45 p.m.
Location: P941, Stevens Salon C, D

Title: “Comparison of Bioreactors and Scale-up of Sf9-Baculovirus Systems for rAAV Production”
Date/time: Friday, May 18, 2018, 5:45 p.m.
Location: P942, Stevens Salon C, D

Voyager investor and analyst breakfast event at ASGCT:

Voyager’s senior management team will review data being presented at the ASGCT meeting during the following webcasted event:

Date/time: Friday, May 18, 2018, 7:30 a.m. CDT 
Location: Joliet Room, 3^rd Floor, Hilton Chicago Hotel, 720 S. Michigan Ave., Chicago, Ill.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. Voyager’s pipeline focuses on severe neurological diseases in need of effective new therapies, including Parkinson’s disease, a monogenic form of ALS called SOD1, Huntington’s disease, Friedreich’s ataxia, neurodegenerative diseases related to defective or excess aggregation of tau protein in the brain including Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, AbbVie, and the University of Massachusetts Medical School.  Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. 

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding the initiation, timing, progress and reporting of results of its preclinical programs and clinical trials and its research and development programs, its ability to advance its AAV-based gene therapies into, and successfully initiate, enroll and complete, clinical trials, the potential clinical utility of its product candidates, its ability to continue to develop its product engine, its ability to develop manufacturing capability for its products and successfully transition its manufacturing process, its ability to perform under existing collaborations with, among others, Sanofi Genzyme and AbbVie and to add new programs to its pipeline, its ability to enter into new partnerships or collaborations, and the timing or likelihood of its regulatory filings and approvals, are forward looking. All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected.  Such risks and uncertainties include, among others, the initiation and conduct of preclinical studies and clinical trials; the availability of data from clinical trials; the expectations for regulatory submissions and approvals; the continued development of the product engine; Voyager’s scientific approach and general development progress; and the availability or commercial potential of Voyager’s product candidates. These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made.  Voyager undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations:   
Matt Osborne
Vice President of Investor Relations & Corporate Communications
857-259-5353
mosborne@vygr.com  

Media:           
Katie EnglemanPure Communications, Inc.
910-509-3977
Katie@purecommunicationsinc.com

Source: Voyager Therapeutics, Inc.